Tadalafil is under clinical development by IntelGenx and currently in the Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tadalafil’s likelihood of approval (LoA) and phase transition for Erectile Dysfunction took place on 30 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tadalafil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tadalafil (INT-0007) is under development for the treatment of erectile dysfunction (ED). It is an oral film formulation. INT-007 is developed using quick-release water technology called Versafilm. This technology utilizes a strip of thin polymeric film, which instantly releases the drug candidate.
IntelGenx is a Canadian oral drug delivery company. It develops pharmaceutical oral films based on its proprietary technology platform, VersaFilm.
Quick View Tadalafil LOA Data
|Highest Development Stage|